VEGF Receptor 2 (KDR) (esKDR) Rabbit Polyclonal Antibody

Specifications

Product Data
Applications	IF, WB
Recommend Dilution	Western blot: 1-5 μg/ml.  Immunofluorescence/Immunohistochemistry: 1-5 µg/ml.
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Immunogen	Peptide consisting of the unique C-terminal end of esKDR: CGRETILDHSAEAVGMP
Specificity	This antibody detects CD309 / VEGFR-2 / Flk-1.  This poyclonal antibody directed against the unique C-terminal end of the endogenous sKDR (CGRETILDHSAEAVGMP) recognizing solely the endogenous form but not sKDR (D7) and sKDR (D7)-Fc consisting of the full extraplasmatic domain. The endogenous sKDR generated by alternative splicing consists of the first 6 Ig-like loops with a unique c-terminal end.
Formulation	PBS, pH 7.2 State: Purified State: Lyophilized purified IgG fraction
Reconstitution Method	Restore in sterile water to a concentration of 0.1-1.0 mg/ml.
Purification	Protein A Chromatography
Conjugation	Unconjugated
Storage Condition	Store lyophilized at 2-8°C for 6 months or at -20°C long term. After reconstitution store the antibody undiluted at 2-8°C for one month  or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing.
Gene Name	kinase insert domain receptor
Database Link	Entrez Gene 3791 Human UniProt ID P35968
Background	Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema. Recombinant human esKDR generated by alternative splicing consist of the first 6 Ig-like loops followed by the unique C-terminal end: CGRETILDHSAEAVGMP.
Synonyms	VEGFR2, FLK1, KDR, VEGF Receptor 2
Reference Data
Protein Families	Druggable Genome, ES Cell Differentiation/IPS, Protein Kinase, Transmembrane
Protein Pathways	Cytokine-cytokine receptor interaction, Endocytosis, Focal adhesion, VEGF signaling pathway

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.